Hoth Therapeutics shares surge 13.08% premarket after securing Chinese patent for HT-KIT cancer technology, expanding IP protection in key oncology market.

Hoth Therapeutics surged 13.08% in premarket trading following the announcement that the China National Intellectual Property Administration approved a key patent covering its HT-KIT cancer program. The patent, stemming from a PCT international application, expands the company’s intellectual property protection in China, one of the world’s largest oncology markets, and validates the HT-KIT platform’s potential to induce apoptosis in cancer cells by targeting KIT signaling pathways. The CEO emphasized that this milestone strengthens Hoth’s global IP position and enhances the strategic and commercial value of HT-KIT, particularly in a jurisdiction critical for oncology innovation and partnerships. The approval reinforces investor confidence in the company’s IP-driven drug development strategy, aligning with the significant premarket price increase.